compliance issues reimbursing glp-1 weight loss treatments multiple states CMS Coverage Guidance on Anti-Obesity Drugs The Skinny on Emerging GLP-1

GLP-1 Drugs Breaking Boundaries: Beyond Diabetes and Obesity Glucagon-like peptide 1 (GLP-1) therapies are not just for diabetes and obesity anymorethey are rewriting the rules of modern medicine

List JF, He H, Habener JF

Subcutaneous (SQ) injection is a shot of medicine into the fatty tissue just below your skin

These compounds should be treated as educational topics, not first-line options for a Manhattan wellness center page

Hepatol Res 45(3):269278 Errafii K, Khalifa O, Al-Akl NS, Arredouani A (2022) Comparative transcriptome analysis reveals that Exendin-4 improves steatosis in HepG2 cells by modulating signaling pathways related to lipid metabolism

and 3) increased glucose production by the liver due to excessive gluconeogenesis